A carregar...

Linezolid Therapy of Staphylococcus aureus Experimental Osteomyelitis

The in vivo activity of linezolid or cefazolin against a clinical isolate of methicillin-susceptible Staphylococcus aureus (linezolid MIC, 2 μg/ml) was studied in a rat model of experimental osteomyelitis. Sixty rats with experimental S. aureus osteomyelitis were treated for 21 days with no antimicr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Patel, Robin, Piper, Kerryl E., Rouse, Mark S., Steckelberg, James M.
Formato: Artigo
Idioma:en
Publicado em: American Society for Microbiology 2000
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC90219/
https://ncbi.nlm.nih.gov/pubmed/11083654
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
id pubmed-90219
record_format dspace
spelling pubmed-902192002-09-12 Linezolid Therapy of Staphylococcus aureus Experimental Osteomyelitis Patel, Robin Piper, Kerryl E. Rouse, Mark S. Steckelberg, James M. Antimicrob Agents Chemother Experimental Therapeutics The in vivo activity of linezolid or cefazolin against a clinical isolate of methicillin-susceptible Staphylococcus aureus (linezolid MIC, 2 μg/ml) was studied in a rat model of experimental osteomyelitis. Sixty rats with experimental S. aureus osteomyelitis were treated for 21 days with no antimicrobial, with 25 μg of linezolid per kg of body weight administered intraperitoneally twice or three times a day, or with 50 μg of cefazolin per kg administered intramuscularly three times a day. After treatment, the animals were sacrificed and the infected tibiae were processed for quantitative bacterial cultures. The results of treatment were expressed as log(10) CFU/gram of bone and analyzed by rank sum analysis. The results of linezolid treatment were not significantly different from those of untreated controls, while cefazolin treatment was significantly more active than no treatment or linezolid treatment. American Society for Microbiology 2000-12 /pmc/articles/PMC90219/ /pubmed/11083654 Text en Copyright © 2000, American Society for Microbiology
institution US National Library of Medicine
collection PubMed Central
language en
format Article
topic Experimental Therapeutics
spellingShingle Experimental Therapeutics
Patel, Robin
Piper, Kerryl E.
Rouse, Mark S.
Steckelberg, James M.
Linezolid Therapy of Staphylococcus aureus Experimental Osteomyelitis
description The in vivo activity of linezolid or cefazolin against a clinical isolate of methicillin-susceptible Staphylococcus aureus (linezolid MIC, 2 μg/ml) was studied in a rat model of experimental osteomyelitis. Sixty rats with experimental S. aureus osteomyelitis were treated for 21 days with no antimicrobial, with 25 μg of linezolid per kg of body weight administered intraperitoneally twice or three times a day, or with 50 μg of cefazolin per kg administered intramuscularly three times a day. After treatment, the animals were sacrificed and the infected tibiae were processed for quantitative bacterial cultures. The results of treatment were expressed as log(10) CFU/gram of bone and analyzed by rank sum analysis. The results of linezolid treatment were not significantly different from those of untreated controls, while cefazolin treatment was significantly more active than no treatment or linezolid treatment.
author Patel, Robin
Piper, Kerryl E.
Rouse, Mark S.
Steckelberg, James M.
author_facet Patel, Robin
Piper, Kerryl E.
Rouse, Mark S.
Steckelberg, James M.
author_sort Patel, Robin
title Linezolid Therapy of Staphylococcus aureus Experimental Osteomyelitis
title_short Linezolid Therapy of Staphylococcus aureus Experimental Osteomyelitis
title_full Linezolid Therapy of Staphylococcus aureus Experimental Osteomyelitis
title_fullStr Linezolid Therapy of Staphylococcus aureus Experimental Osteomyelitis
title_full_unstemmed Linezolid Therapy of Staphylococcus aureus Experimental Osteomyelitis
title_sort linezolid therapy of staphylococcus aureus experimental osteomyelitis
publisher American Society for Microbiology
publisher_facet American Society for Microbiology
publishDate 2000
url https://ncbi.nlm.nih.gov/pmc/articles/PMC90219/
https://ncbi.nlm.nih.gov/pubmed/11083654
_version_ 1759029391844704256